TY - JOUR
T1 - Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes
AU - Narimatsu, Shizuo
AU - Yonemoto, Rei
AU - Masuda, Kazufumi
AU - Katsu, Takashi
AU - Asanuma, Masato
AU - Kamata, Tooru
AU - Katagi, Munehiro
AU - Tsuchihashi, Hitoshi
AU - Kumamoto, Takuya
AU - Ishikawa, Tsutomu
AU - Naito, Shinsaku
AU - Yamano, Shigeru
AU - Hanioka, Nobumitsu
N1 - Funding Information:
We would like to express our gratitude to Dr. M. Funada, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan. This study was supported in part by Grants-in-Aid for Scientific Research (17390035 and 18590116) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
PY - 2008/2/1
Y1 - 2008/2/1
N2 - The oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), a tryptamine-type designer drug, was studied using rat liver microsomal fractions and recombinant cytochrome P450 (CYP) enzymes. 5-MeO-DIPT was biotransformed mainly into a side-chain N-deisopropylated metabolite and partially into an aromatic ring O-demethylated metabolite in liver microsomal fractions from untreated rats of both sexes. This metabolic profile is different from our previous findings in human liver microsomal fractions, in which the aromatic ring O-demethylation was the major pathway whereas the side-chain N-deisopropylation was minor [Narimatsu S, Yonemoto R, Saito K, Takaya K, Kumamoto T, Ishikawa T, et al. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2006;71:1377-85]. Kinetic and inhibition studies indicated that the side-chain N-dealkylation is mediated by CYP2C11 and CYP3A2, whereas the aromatic ring O-demethylation is mediated by CYP2D2 and CYP2C6 in untreated male rats. Pretreatment of male rats with β-naphthoflavone (BNF) produced an aromatic ring 6-hydroxylated metabolite. Recombinant rat and human CYP1A1 efficiently catalyzed 5-MeO-DIPT 6-hydroxylation under the conditions used. These results provide valuable information on the metabolic fate of 5-MeO-DIPT in rats that can be used in the toxicological study of this designer drug.
AB - The oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), a tryptamine-type designer drug, was studied using rat liver microsomal fractions and recombinant cytochrome P450 (CYP) enzymes. 5-MeO-DIPT was biotransformed mainly into a side-chain N-deisopropylated metabolite and partially into an aromatic ring O-demethylated metabolite in liver microsomal fractions from untreated rats of both sexes. This metabolic profile is different from our previous findings in human liver microsomal fractions, in which the aromatic ring O-demethylation was the major pathway whereas the side-chain N-deisopropylation was minor [Narimatsu S, Yonemoto R, Saito K, Takaya K, Kumamoto T, Ishikawa T, et al. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2006;71:1377-85]. Kinetic and inhibition studies indicated that the side-chain N-dealkylation is mediated by CYP2C11 and CYP3A2, whereas the aromatic ring O-demethylation is mediated by CYP2D2 and CYP2C6 in untreated male rats. Pretreatment of male rats with β-naphthoflavone (BNF) produced an aromatic ring 6-hydroxylated metabolite. Recombinant rat and human CYP1A1 efficiently catalyzed 5-MeO-DIPT 6-hydroxylation under the conditions used. These results provide valuable information on the metabolic fate of 5-MeO-DIPT in rats that can be used in the toxicological study of this designer drug.
KW - 5-Methoxy-N,N-diisopropyltryptamine
KW - 6-Hydroxylation
KW - CYP1A1
KW - CYP2C11
KW - CYP2D2
KW - CYP3A2
KW - N-Deisopropylation
KW - O-Demethylation
KW - Rat
UR - http://www.scopus.com/inward/record.url?scp=37849008946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37849008946&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2007.09.019
DO - 10.1016/j.bcp.2007.09.019
M3 - Article
C2 - 17980859
AN - SCOPUS:37849008946
VL - 75
SP - 752
EP - 760
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
SN - 0006-2952
IS - 3
ER -